antiviral-agents

Documents about antiviral-agents

• Ocoxin oral solution demonstrates antiviral properties in cellular models#287864Gestión del Repositorio Documental de la Universidad de Salamanca
• "Metal-based compounds in antiviral and Antiparasitic research: Mechanistic insights from HIV NCp7 and leishmaniasis case studies".#190383PubMed
• Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C#849120ClinicalTrials.gov
• Synthesis and characterization of new HIV-1 antiviral agents#651452Dipòsit Digital de la Universitat de Barcelona
• Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection.#327635Repisalud
• Polyphenols as Antiviral Agents: Their Potential Against a Range of Virus Types#318948HAL (France)
• Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents#330316HAL (France)
• Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products#833901ClinicalTrials.gov
• The Mochudi Prevention Project ART Protocol#886999ClinicalTrials.gov
• Direct-Acting Antiviral Agents in Hepatitis C–Associated Indolent Lymphomas#264880IRIS
• Risk of Interstitial Lung Disease in COVID-19 Patients with Autoimmune Diseases Treated with Antiviral Agents#191545bioRxiv / medRxiv
• Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030#151807WHO IRIS
• Natural Killer Cell (CYNK-001) Infusions in Adults with AML#898774ClinicalTrials.gov
• Enriched Heparin Anti COVID-19 Trial#880523ClinicalTrials.gov
• Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage.#631505PubMed
• A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients#860310ClinicalTrials.gov
• Recent advances in drug discovery for Zika virus therapeutics.#18525PubMed
• A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.#682935Apollo
• The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine#884739ClinicalTrials.gov
• Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.#309484PubMed
• VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1#828958ClinicalTrials.gov
• Unraveling the role of casein kinase 2 in the SARS-CoV-2 lifecycle : Implications for host-targeted antiviral development#124513HAL (France)
• Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia#900259ClinicalTrials.gov
• Opciones terapéuticas y COVID-19: orientaciones evolutivas, 10 de noviembre de 2023#356067WHO IRIS
• Increasing competition in pharmaceutical tenders: Patents, treatment guidelines, and centralised procurement of Hepatitis C drugs in Brazil.#400691PubMed
• Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma#886850ClinicalTrials.gov
• Synthesis of 5,5-difluoro-5-phosphono-pent-2-en-1-yl nucleosides as potential antiviral agents#7972HAL (France)
• A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients#801198ClinicalTrials.gov
• A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection#849004ClinicalTrials.gov
• Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection#969598ClinicalTrials.gov
• A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis#837779ClinicalTrials.gov
• Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)#980126ClinicalTrials.gov
• Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants.#823908Repisalud
• the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19#864365ClinicalTrials.gov
• Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver#901731ClinicalTrials.gov
• A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems#833728ClinicalTrials.gov
• A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children#846909ClinicalTrials.gov
• A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine#1009225ClinicalTrials.gov
• The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs#810911ClinicalTrials.gov
• Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.#672219Repisalud
• Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.#831707ClinicalTrials.gov
• The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients#836620ClinicalTrials.gov
• Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients#887191ClinicalTrials.gov
• Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.#281631Repisalud
• SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir#856693ClinicalTrials.gov
• The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS#889117ClinicalTrials.gov
• Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome#894729ClinicalTrials.gov
• Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir#917847ClinicalTrials.gov
• Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C#1008301ClinicalTrials.gov
• Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection#838401ClinicalTrials.gov